Concord Biotech Limited

Concord Biotech Limited, established in 2000, is a leading Indian biopharmaceutical company specializing in the research, development, and manufacturing of fermentation-based Active Pharmaceutical Ingredients (APIs) and finished formulations. Headquartered in Ahmedabad, Gujarat, India, the company has expanded its global footprint, serving over 70 countries with a diverse product portfolio.

The company operates with a vertically integrated business model, encompassing API production, formulation development, and contract research and manufacturing services. This integration enables Concord Biotech to maintain stringent quality control and meet the evolving demands of the global pharmaceutical market.

Concord Biotech Limited operates three state-of-the-art manufacturing facilities near Ahmedabad, Gujarat, India, each designed to meet international quality standards.

The Dholka facility, established in 2000, spans 112,302 square meters and comprises 22 manufacturing blocks. It specializes in the production of fermentation and semi-synthetic APIs, with a fermentation capacity of 450m³. This facility has been inspected and approved by global regulatory agencies, including the USFDA, EU GMP, Japanese PMDA, and ANVISA of Brazil.

In 2021, Concord Biotech commissioned the Limbasi facility, covering 596,309 square meters with 19 manufacturing blocks, including six fermentation blocks and 13 downstream processing blocks. This facility boasts a fermentation capacity of 800m³ and is equipped to handle complex fermentation and downstream processing, catering to major regulated markets.

The Valthera facility focuses on the production of finished formulations, including oral solids, oral liquids, and suspensions. It is designed to meet global regulatory standards such as USFDA and EU GMP, targeting both domestic and international markets.

Concord Biotech Limited is led by a team of seasoned professionals committed to driving the company's growth and innovation.

Mr. Sudhir Vaid serves as the Chairman and Managing Director. With a background in microbiology and extensive experience in the pharmaceutical industry, he has been instrumental in transforming Concord Biotech into a global leader in fermentation-based biopharmaceuticals.

Mr. Ankur Vaid, the Joint Managing Director and Chief Executive Officer, holds a B.Tech in Chemical Engineering and an MBA. With over 18 years in the pharmaceutical industry, he has been pivotal in leading key initiatives in research, development, and market strategy, contributing significantly to the company's success.

Concord Biotech Limited has established a strong presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan, through rigorous regulatory filings and approvals.

In the United States, the company's Dholka facility has undergone multiple inspections by the USFDA, resulting in successful approvals for the manufacturing of various APIs. This facility is also registered with the FDA, allowing Concord Biotech to market its products in the U.S. market.

In the European Union, the Dholka facility has been inspected and approved by the EU GMP, Government of Upper Bavaria, ensuring compliance with European manufacturing standards. This approval facilitates the export of Concord Biotech's products to EU member countries.

In Japan, the company has received Drug Master File (DMF) registrations for Tacrolimus Hydrate from the Pharmaceuticals and Medical Devices Agency (PMDA), enabling the marketing of its products in the Japanese market.

Concord Biotech's commitment to quality and compliance has also led to approvals in other regulated markets, including Australia and the United Kingdom, further solidifying its global footprint.

Concord Biotech Limited has strategically expanded its presence in emerging markets across Africa, Latin America, and Southeast Asia, leveraging WHO prequalification to enhance market access.

The company's finished formulations, including oral solids, liquids, and suspensions, are marketed under its own brands in India and distributed across emerging markets in Asia, Africa, Latin America, and the United States through established partnerships.

By obtaining WHO prequalification, Concord Biotech has facilitated the entry of its products into these markets, ensuring compliance with international quality standards and enhancing the company's reputation as a reliable supplier of pharmaceutical products.

Concord Biotech Limited's geographic strategy demonstrates a balanced approach to market diversification and risk management.

The company's significant presence in over 70 countries, including both regulated and emerging markets, indicates a well-diversified portfolio that mitigates concentration risks. This global footprint allows Concord Biotech to leverage growth opportunities across different regions while maintaining a stable revenue stream.

Strategically, Concord Biotech continues to focus on expanding its reach in emerging markets, capitalizing on the increasing demand for quality pharmaceutical products. Simultaneously, the company maintains a strong foothold in regulated markets, ensuring compliance with stringent regulatory standards and reinforcing its reputation as a trusted pharmaceutical manufacturer.

Concord Biotech Limited has a robust standing with the U.S. Food and Drug Administration (FDA), underscoring its commitment to quality and regulatory compliance.

The Dholka facility has been inspected multiple times by the USFDA, resulting in successful approvals for the manufacturing of various APIs. This facility is registered with the FDA, enabling Concord Biotech to market its products in the U.S. market.

The company's adherence to cGMP standards and its proactive approach to regulatory compliance have facilitated these approvals, allowing Concord Biotech to supply high-quality pharmaceutical products to the U.S. market.

Concord Biotech Limited's commitment to quality is demonstrated through its compliance with WHO and EU GMP standards.

The Dholka facility has been inspected and approved by the EU GMP, Government of Upper Bavaria, ensuring compliance with European manufacturing standards. This approval facilitates the export of Concord Biotech's products to EU member countries.

Additionally, the Valthera formulation facility has received inspections from the WHO for GMP, further validating the company's adherence to international quality standards.

Concord Biotech Limited operates in full compliance with the Central Drugs Standard Control Organisation (CDSCO) and other Indian regulatory authorities.

The company's manufacturing facilities hold the necessary licenses and approvals from the CDSCO, ensuring adherence to national standards for pharmaceutical manufacturing. Concord Biotech also maintains state drug controller approvals and export No Objection Certificates (NOCs), facilitating the export of its products to various international markets.

As of March 28, 2026, there have been no publicly reported Form 483 observations, warning letters, or import alerts issued to Concord Biotech Limited by the U.S. Food and Drug Administration (FDA). The company's manufacturing facilities have consistently met regulatory standards, reflecting its commitment to quality and compliance.

Concord Biotech Limited operates in a competitive landscape, with several key players in the biopharmaceutical industry offering similar products.

In the immunosuppressant segment, competitors include companies like Novartis and Roche, which have established market presence and extensive product portfolios. In oncology, firms such as Pfizer and Merck are prominent, offering a range of oncology therapeutics.

Concord Biotech's focus on fermentation-based APIs and high-quality formulations positions it as a specialized player in the market. The company's commitment to quality, regulatory compliance, and a diversified product portfolio enables it to maintain a competitive edge in the industry.

Concord Biotech Limited distinguishes itself through several key differentiators:

• Specialized Manufacturing Capabilities: The company's expertise in fermentation and semi-synthetic processes allows for the production of complex APIs and formulations, catering to niche therapeutic segments.

• Regulatory Compliance: Concord Biotech's facilities are inspected and approved by multiple global regulatory agencies, including the USFDA, EU GMP, and WHO, ensuring adherence to international quality standards.

• Global Presence: With a footprint in over 70 countries, the company has established a robust distribution network, enabling it to serve diverse markets effectively.